Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA).

IO, Rosas; N, Bräu; M, Waters; RC, Go; A, Malhotra; BD, Hunter; S, Bhagani; D, Skiest; S, Savic; IS, Douglas; J, Garcia-Diaz; MS, Aziz; N, Cooper; T, Youngstein; LD, Sorbo; DJ, Zerda; A, Ustianowski; AC, Gracian; KG, Blyth; J, Carratalà; B, François; T, Benfield; D, Haslem; P, Bonfanti; der Leest CH, van; N, Rohatgi; L, Wiese; CE, Luyt; RN, Bauer; F, Cai; IT, Lee; B, Matharu; L, Metcalf; S, Wildum; E, Graham; L, Tsai; M, Bao

doi:10.1016/j.eclinm.2022.101409

Public

Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA).

Shared by NobleBlocks on Apr 21, 2022 • 12:00 AM UTC

Authors:

Rosas IO

Bräu N

Waters M

Abstract

Background In COVACTA, a randomised, placebo-controlled trial in patients hospitalised with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day mortality, but shortened hospital and intensive care unit stay. Longer-term effects of tocilizumab in patients with COVID-19 are unknown. ...

Subject

Interleukin-6

Viral load

Tocilizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!